Pemetrexed - EVER Pharma Italia

Dosage Form	Concentrate for solution for infusion
Strength	25 mg/ml
Strength per Unit	100 mg/4 ml, 500 mg/20 ml, 1000 mg/40 ml
ATC Code	L01BA04
Drug Class	Antineoplastic agents, folic acid analogues
Indication	Malignant pleural mesothelioma Pemetrexed in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. Non-small cell lung cancer Pemetrexed in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.1). Pemetrexed is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5.1). Pemetrexed is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.1).

Pemetrexed EVER Pharma is a prescription medication. Information for healthcare professionals only.
See the Summary of Product Characteristics for full information about the medication.